Lymphoma
Conditions
Brief summary
RATIONALE: Imaging procedures, such as positron emission tomography or computed tomography, may help in detecting differences between Hodgkin lymphoma or diffuse large B-cell lymphoma cancer cells. PURPOSE: This clinical trial is studying positron emission tomogaphy and computed tomography in determining differences in Hodgkin lymphoma and diffuse large B-cell lymphoma.
Detailed description
OBJECTIVES: I. Assess the feasibility of detection and quantification of differences in the temporal and spatial distribution of FDG uptake between lesions of HL and DLBCL. OUTLINE: Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans 60 and 180 minutes after FDG administration. After completion of study, patients are followed for 24 hours.
Interventions
RADIATIONFludeoxyglucose F18
Undergo FDG PET/CT scans
PROCEDUREComputed Tomography
Undergo FDG PET/CT scans
PROCEDUREPositron emission tomography
Undergo FDG PET/CT scans
Sponsors
Abramson Cancer Center at Penn Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects with a pathologically-proven diagnosis of classic HL or DLBCL with measurable disease by any imaging technique or physical examination.
Exclusion criteria
* Pregnant or nursing, * Uncontrolled diabetes mellitus, * Active infection, * Inability to give informed consent or to comply with all study procedures, * Subjects may be excluded at the discretion of the principal investigator or study team members.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage Change in Maximum Lesional FDG Uptake From 60 to 180 Minutes After FDG Administration | 2 hours (between 60 minutes post-administration and 180 minutes post-administration) | Lesional fluorodeoxyglucose (FDG) uptake is measured by standardized uptake value (SUV). The study compared the percentage of change in maximum SUV over 2 hours (first measure was 60 minutes post-administration and second timepoint was 180 minutes post-administration). |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Fludeoxyglucose F18 (FDG) PET/CT Scans Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans and 180 minutes after FDG administration.
Fludeoxyglucose F18: Undergo FDG PET/CT scans
Computed Tomography: Undergo FDG PET/CT scans
Positron emission tomography: Undergo FDG PET/CT scans | 10 |
| Total | 10 |
Baseline characteristics
| Characteristic | Fludeoxyglucose F18 (FDG) PET/CT Scans |
|---|---|
| Age, Continuous | 47 years |
| Region of Enrollment United States | 10 participants |
| Sex: Female, Male Female | 4 Participants |
| Sex: Female, Male Male | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 0 / 10 |
| serious Total, serious adverse events | 0 / 10 |
Outcome results
Primary
Percentage Change in Maximum Lesional FDG Uptake From 60 to 180 Minutes After FDG Administration
Lesional fluorodeoxyglucose (FDG) uptake is measured by standardized uptake value (SUV). The study compared the percentage of change in maximum SUV over 2 hours (first measure was 60 minutes post-administration and second timepoint was 180 minutes post-administration).
Time frame: 2 hours (between 60 minutes post-administration and 180 minutes post-administration)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Diffuse Large B-cell Lymphoma | Percentage Change in Maximum Lesional FDG Uptake From 60 to 180 Minutes After FDG Administration | 36.2 percentage of change in maximum SUV | Standard Deviation 12.4 |
| Hodgkin's Lymphoma | Percentage Change in Maximum Lesional FDG Uptake From 60 to 180 Minutes After FDG Administration | 32 percentage of change in maximum SUV | Standard Deviation 11.6 |